Ji-Young Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ji-Young Jang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Bhumsuk Keam
Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea
9 shared publications - Chul Woo Kim
Bioinfra Co. Ltd., 7th Cancer Research Institute, 49 Daehak-ro, Yeongun-dong, Jongro-gu, Seoul, Republic of Korea
9 shared publications - Soo Jeong Nam
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
9 shared publications - Yong-Goo Kim
Department of Herbal Crop Research, National Institute of Horticultural & Herbal Science, RDA, Eumseong 27709, Republic of Korea
9 shared publications - Yoon Kyung Jeon
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
9 shared publications - Tae Min Kim
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
8 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
The sensitiviy of gefitinib in various NSCLC cell lines from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessThe sensitiviy of gefitinib in various NSCLC cell lines from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Mitochondrial inhibitor, lonidamin suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMitochondrial inhibitor, lonidamin suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
The sensitiviy of gefitinib in various NSCLC cell lines from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessThe sensitiviy of gefitinib in various NSCLC cell lines from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
The inhibition of ANT2 suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessThe inhibition of ANT2 suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Down-regulation of ANT2 protein levels by shRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessDown-regulation of ANT2 protein levels by shRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Down-regulation of ANT2 protein levels by shRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessDown-regulation of ANT2 protein levels by shRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Mitochondrial inhibitor, lonidamin suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMitochondrial inhibitor, lonidamin suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
The inhibition of ANT2 suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Apoptosis analysis: cells were transfected with ANT2-specific shRNA or sc shRNA. At 24 h after transfection, the cells were treated with gefitinib (50 nM) or DMSO as a control and subsequently incubated for an additional 24 h. Then, cell were stained with annexin V-fluorescence isothiocyanate (FITC) and propidium iodide (PI) for flow cytometry analysis. Data are representative of three independent experiments.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessThe inhibition of ANT2 suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Apoptosis analysis: cells were transfected with ANT2-specific shRNA or sc shRNA. At 24 h after transfection, the cells were treated with gefitinib (50 nM) or DMSO as a control and subsequently incubated for an additional 24 h. Then, cell were stained with annexin V-fluorescence isothiocyanate (FITC) and propidium iodide (PI) for flow cytometry analysis. Data are representative of three independent experiments.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Down-regulation of ANT2 and HSP90 mRNA levels by siRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessDown-regulation of ANT2 and HSP90 mRNA levels by siRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
- Open Access
- 20 February 2022
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 24, 683-694
A host non-coding RNA, nc886, plays a pro-viral role by promoting virus trafficking to the nucleus
- 20 February 2022
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 24, 683-694
Open AccessA host non-coding RNA, nc886, plays a pro-viral role by promoting virus trafficking to the nucleus